INTRODUCTION

Ψ
Diabetes mellitus (DM) is a leading cause of morbidity and mortality all over the world. It is considered an ambulatory care-sensitive condition in which many hospitalizations are potentially preventable 1 . There is compelling evidence from randomized, controlled trials that diabetic microangiopathy and neuropathy can be reduced by tight glycemic control 2, 3 . A favorable influence on macrovascular complications has also been observed when glycemic control is tight in diabetics 4 . In type 1 DM, the gold standard of treatment, which is aimed at glycated hemoglobin (HbA1c) <7%, is intensive insulin therapy, appropriate nutrition and blood glucose selfmonitoring.
However, such common Ψ Correspondence at: Department of Medicine, Federal Medical Centre, Ido Ekiti, Nigeria; Email: lifecareado@gmail.com pharmacological treatment approach is less well accepted in type 2 DM. The Diabetes Complications and Control Trial recommended HbA1c <7% as accepted target for diabetes management 5 , though there is fear that aggressive diabetes control with HbA1C <6% may be detrimental in CVD patients; hence it is pertinent to closely watch for latest consensus guidelines for tight glycemic control 6 . Nonetheless, various diabetes associations have advocated target fasting plasma glucose (FPG) as tools for assessing glycemic control in DM. For instance, the American Diabetes Association's (ADA) FPG target is <6.7mmol/L 7 and ≤ 6.0 mmol/L for International Diabetes Federation -Europe (IDFEurope) 8 . Disappointingly, two-thirds of people with diabetes are currently above this target
9
. The use of target FPG to monitor glycemic control is relevant in the developing and resource-scarce countries where facilities for HbA1c are scarce and affordability for patients is still a serious issue. Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved In DM, hypertension often co-exist 10 and it is up to three times more common in type 2 DM than nondiabetic subjects 11 . In the presence of obesity, increasing age and onset of renal disease, the prevalence of hypertension in diabetic patients is further increased. Control of blood pressure (BP) to target in diabetics is as important as tight glycemic control to lower the severity and progression of cardiovascular complications. The United Kingdom Prospective Diabetes Study (UKPDS) and Hypertension Optimal Treatment (HOT) study revealed that an intensive blood pressure-lowering treatment strategy is associated with a lower incidence of cardiovascular complications in patients with diabetes 12, 13 . Studies reveal that many patients with DM do not reach the recommended target of a blood pressure (BP) <130mmHg systolic and <80mmHg diastolic 14 
.
Little is known about how many type 2 diabetic patients have specific target BP, blood glucose and BMI in Ekiti area of Nigeria. In light of this, we conducted a retrospective study of type 2 diabetics attending out-patient clinics (a) to determine what proportion of patients with diabetes have fasting plasma glucose and BP to targets; (b) to determine patient characteristics associated with having a blood glucose and BP target; (c) to determine the pattern of prescription of medications in these patients. 
METHODOLOGY
Glycemic, Blood Pressure and weight control
Using the IDF-EUROPE control target of <6.0mmol/L (Figure 1) , 29.3% of the patients had target mean FPG control. Only 32.5% of the patients had mean FPG control with the ADA control target of <6.7mmol/L. Those with target glucose control using either IDF-Europe or ADA criteria were significantly older with longer duration of clinic attendance ( Table 2 ). There were Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved no significant differences in their BMI and BP. 
DISCUSSION
In this study, there was high prevalence of hypertension coexisting with diabetes (76.3%). These diabetic patients with coexisting hypertension were found to be older than the mean age of the study population and had significantly higher BMI than those without coexisting hypertension. They also had been attending clinic for a longer duration than those without hypertension. Their mean FPG levels were however comparable.
It is likely, from the foregoing, that these hypertensive diabetics have had their diabetes for a longer duration than those without hypertension. The proportion of patients who achieved target BP control of <130/80mmHg was disappointingly low (24.5%) despite the fact that all the hypertensive patients were identified and placed on antihypertensive medications. It is noteworthy that combination antihypertensive medications were employed in just about half of the hypertensive diabetic patients. Out of these patients on combination antihypertensive drugs, 90.3% were on two antihypertensive drugs while only 9.7% were on combination of three antihypertensive drugs. To achieve satisfactory BP control in DM, multiple drugs therapy is often required 15 . It has even been suggested that a combination of at least three drugs are required in patients whose systolic BP is about 25-30 mmHg above the target goal 16 . Inadequate BP control in the majority of a group of patients with DM had been in Nigeria. In one study, only 11% of diabetic patients with hypertension had their BP controlled to levels below 140/90mmHg. 17 Similarly, Arije et al 18 in a study in an urban teaching hospital in southwestern Nigeria, observed that approximately 12% of their patients achieved BP control below the currently recommended target level of 130/80 mmHg. In a different study of BP control among hypertensive patients in a tertiary health care setting in northern Nigeria, a normal blood pressure control incidence of approximately 43% was reported using a blood pressure cut-off value of 140/90 mmHg
19
. Several other studies in more economically advanced environments showed that achieving the target blood pressure goal is often difficult 20 as only a minority of the patients studied had their BP controlled below the recommended target. Considering the poor BP control rate among these patients, it becomes necessary to emphasize the need to the attending physicians of the necessity of multiple drug therapy with at least three different classes of antihypertensive drugs for hypertensive diabetic patients in order to achieve target BP.
Patients' compliance with medications should also be stressed and fixed dose antihypertensive drugs combinations may be employed to enhance patients drug adherence. Generally, the proportion of our study population who attained target glycemic level with either the IDF-Europe or ADA criteria was very low (29.3% and 32.5% respectively), though comparable with what had earlier been reported in other studies across the world. In a study on glycemic control rates among US adults with type 2 diabetes from 1999 to 2000 8 , less than 36% of patients reached a HbA1c goal of less than 7%. In a subset of diabetic patients with retinopathy in Australia, only 14% (36/259) had an optimal HbA1c level
21
. In a South African township, fasting blood glucose levels were <7.0 mmol/l in only 17.6% of the patients 22 . Maintenance of tight glycemic control in patients with type 2 diabetes requires timely adjustments and changes in therapy when goals are not met. While the majority are initially treated with oral antidiabetic drugs (OHAs) 23 , most patients ultimately require insulin therapy to maintain glycemic control 24 due to progressive pancreatic ß-cell dysfunction and/or failure. Insulin use is low in our patients as only 3.3% were on insulin alone and another 2.0% were on insulin combined with OHA. This may partly account for the poor glucose control in these patients. Similarly, a low insulin use has been noted by Alebiosu et al in a study from Sagamu, south western Nigeria 25 . However a higher percentage of patients (26.4%) in Ibadan were prescribed insulin compared to the Sagamu study 26 , though the study population consisted of all types of DM. Oral hypoglycemic agents (OHAs), especially metformin and glibenclamide are the commonly prescribed antidiabetic agents in this Ibadan study similar to Sagamu study and our present study. In our study, increasing age and longer duration of clinic attendance appear to be associated with better blood glucose control. About half of the patients in this study were either overweight or obese. Worse still was the high prevalence of coexisting hypertension among this Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved subset of patients (75.3%). Though, there was no correlation between BMI and mean FPG in this study, the high prevalence of poor glycemic, BP and weight control is worrisome. An increase in body fat is generally associated with increased risk of metabolic diseases such as type 2 diabetes mellitus, hypertension and dyslipidemia. There is an urgent need to advocate holistic approach to diabetes management in clinical practice in Nigeria. Another important observation in this study was the low prevalence of the use of antiplatelet agents. Only 37.01% of the patients were placed on low dose aspirin. This is in spite of the fact that daily aspirin intake has been found to reduce vascular events in patients with diabetes 27 . Physicians need to be encouraged to prescribe this relatively cheap but important drug in the management of diabetes. The lipid lowering agents, statins or any other lipid lowering drugs, were not prescribed in the patients. Evidence exists about the benefit of statins in reducing cardiovascular events in diabetic patients independent of lipid levels 28 . It has been recognized that one important factor against frequent use of statin is the high cost, especially in the resourcepoor setting like ours
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.
CONCLUSION
The results from this study showed poor control of blood glucose, BP and weight in the patients. Patients' blood pressure and longer duration of clinic attendance appeared to negatively affect blood glucose control. We are of the opinion that current practices are not aggressive enough to manage a substantial proportion of type 2 diabetes patients. As facilities for glycated hemoglobin are being increasingly available in Nigeria, it may be possible in the nearest future to employ it in monitoring glycemic control in all our DM patients.
